SG11201900551WA - Spiro-lactam nmda receptor modulators and uses thereof - Google Patents
Spiro-lactam nmda receptor modulators and uses thereofInfo
- Publication number
- SG11201900551WA SG11201900551WA SG11201900551WA SG11201900551WA SG11201900551WA SG 11201900551W A SG11201900551W A SG 11201900551WA SG 11201900551W A SG11201900551W A SG 11201900551WA SG 11201900551W A SG11201900551W A SG 11201900551WA SG 11201900551W A SG11201900551W A SG 11201900551WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- compounds
- nmda receptor
- spiro
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000208140 Acer Species 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662369456P | 2016-08-01 | 2016-08-01 | |
PCT/US2017/044841 WO2018026782A1 (en) | 2016-08-01 | 2017-08-01 | Spiro-lactam nmda receptor modulators and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201900551WA true SG11201900551WA (en) | 2019-02-27 |
Family
ID=59593191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900551WA SG11201900551WA (en) | 2016-08-01 | 2017-08-01 | Spiro-lactam nmda receptor modulators and uses thereof |
Country Status (16)
Country | Link |
---|---|
US (3) | US10918637B2 (de) |
EP (1) | EP3490993B1 (de) |
JP (1) | JP7032378B2 (de) |
KR (1) | KR102465757B1 (de) |
CN (1) | CN109890825B (de) |
AU (1) | AU2017305240B2 (de) |
CA (1) | CA3031539C (de) |
CL (1) | CL2019000247A1 (de) |
CO (1) | CO2019000943A2 (de) |
EA (1) | EA201990428A1 (de) |
IL (2) | IL286107B1 (de) |
MX (1) | MX2019001321A (de) |
PE (1) | PE20190504A1 (de) |
PH (1) | PH12019500206A1 (de) |
SG (1) | SG11201900551WA (de) |
WO (1) | WO2018026782A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009293164B2 (en) | 2008-09-18 | 2015-07-09 | Northwestern University | NMDA receptor modulators and uses thereof |
BR112015018087B1 (pt) | 2013-01-29 | 2022-09-20 | Aptinyx Inc | Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos |
KR101518972B1 (ko) | 2014-08-01 | 2015-05-18 | 제이더블유크레아젠 주식회사 | 수지상세포의 제조방법, 이에 의해 제조된 수지상세포 및 그 용도 |
SG11201900551WA (en) | 2016-08-01 | 2019-02-27 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
PE20190501A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores nmda espiro-lactam y metodos de uso de los mismos |
PE20190502A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos |
PE20190503A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos |
PE20190500A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores del receptor nmda spiro-lactam y uso de los mismos |
US11578072B2 (en) | 2018-01-31 | 2023-02-14 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
PE20240926A1 (es) | 2020-06-03 | 2024-04-30 | Aptinyx Inc | Compuestos de espirolactama y metodos para tratar infecciones virales usando los mismos |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0180398A1 (de) | 1984-10-26 | 1986-05-07 | The Regents Of The University Of California | Beta-Lactam-Synthese |
CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
US4904681A (en) | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
EP0360390A1 (de) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactamderivate |
US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
US5350769A (en) | 1990-10-30 | 1994-09-27 | Ss Pharmaceutical Co., Ltd. | Antiinflammatory gel preparation |
US5168103A (en) | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
FR2692268B1 (fr) | 1992-06-15 | 1994-08-19 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations. |
SE9301667D0 (sv) | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | New use |
US5523323A (en) | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
US5741778A (en) | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
CN1130372C (zh) | 1996-06-07 | 2003-12-10 | 曾尼卡有限公司 | 肽衍生物 |
AU3972797A (en) | 1996-08-02 | 1998-02-25 | Zymogenetics Inc. | Testis-specific insulin homolog polypeptides |
US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
JP3955345B2 (ja) | 1996-09-27 | 2007-08-08 | サントリー株式会社 | 新規アミノ酸ダイジハーベイン |
AU1585999A (en) | 1997-11-12 | 1999-05-31 | Neurotherapeutics | Methods for the detection and treatment of disease using a glycosyltransferase |
US5952389A (en) | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
US6274314B1 (en) | 1998-04-02 | 2001-08-14 | Nyxis Neurotherapies, Inc. | Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine |
US6197820B1 (en) | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
US6025471A (en) | 1998-06-03 | 2000-02-15 | Deghenghi; Romano | Diazaspiro, azepino and azabicyclo therapeutic peptides |
WO2000028090A2 (en) | 1998-11-12 | 2000-05-18 | Nyxis, Inc. | Diagnostic assay for cancer |
US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
AU1922301A (en) | 1999-11-17 | 2001-05-30 | Nyxis Neurotherapies, Inc. | Differential gene expression in cancer |
WO2001057240A2 (en) | 2000-02-01 | 2001-08-09 | Agy Therapeutics, Inc. | Interaction of nmda receptor with protein tyrosine phosphatase |
AU2001268467A1 (en) | 2000-06-14 | 2001-12-24 | Nyxis Neurotherapies, Inc. | Identification of genes and compounds for treatment of cancer |
JP2004500874A (ja) | 2000-06-22 | 2004-01-15 | ニクシス ニューロセラピーズ インコーポレーティッド | 低酸素症および関連状態の治療のための神経活性ペプチド |
GB0018272D0 (en) | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
EP1186303A3 (de) | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Ein Neutrophilhemmender Faktor und ein selektive NMDA-NR2B Rezeptor Antagonisten enthaltende Kombinationspräparate zur Behandlung von Schlaganfällen und traumatischen Gehirnschäden |
UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
US20020142287A1 (en) | 2000-12-14 | 2002-10-03 | Hirotaka Yamamoto | High throughput assay to detect inhibitors of the map kinase pathway |
AU2002248553A1 (en) | 2001-03-07 | 2002-09-24 | Cognetix, Inc | Linear y-carboxyglutamate rich conotoxins |
WO2002072609A2 (en) | 2001-03-12 | 2002-09-19 | Nyxis Neurotherapies, Inc | Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain |
WO2003010540A1 (en) | 2001-07-25 | 2003-02-06 | Nyxis Neurotherapies, Inc. | Method of identifying nmda-related agent |
EP1519939B9 (de) | 2002-07-05 | 2011-04-06 | Targacept, Inc. | N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung |
US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
EP1660634A4 (de) | 2003-08-08 | 2009-02-18 | Burnham Inst | P16-vermittelte regulation von nmda-rezeptoren |
US7662856B2 (en) | 2003-08-29 | 2010-02-16 | The University Of Houston System | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine |
GB0323204D0 (en) | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
WO2006034196A1 (en) | 2004-09-17 | 2006-03-30 | Lifelike Biomatic Inc. | Compositions for enhancing memory and methods therefor |
DE602006020353D1 (de) | 2005-03-24 | 2011-04-07 | Univ Emory | Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns |
US20100160255A1 (en) * | 2005-07-29 | 2010-06-24 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
WO2007025141A2 (en) | 2005-08-26 | 2007-03-01 | Wisconsin Alumni Research Foundation | Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same |
AR059224A1 (es) | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
JP2010503677A (ja) | 2006-09-15 | 2010-02-04 | シェーリング コーポレイション | 脂質代謝の障害を治療するためのアゼチジノン誘導体 |
JP2008188285A (ja) | 2007-02-06 | 2008-08-21 | Bridgestone Corp | バックパッド及び車両用シート |
CN101066945B (zh) | 2007-05-25 | 2010-05-19 | 中国科学院上海有机化学研究所 | 一种合成3-位取代内酰胺类化合物的方法 |
CN101125817B (zh) | 2007-08-03 | 2011-09-14 | 中国科学院上海有机化学研究所 | 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法 |
WO2009039390A2 (en) | 2007-09-20 | 2009-03-26 | Naurex Inc. | The development of glycobiology-based therapeutics for the treatment of brain tumors |
WO2009105718A1 (en) | 2008-02-20 | 2009-08-27 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism |
EP2293777B1 (de) | 2008-06-24 | 2015-02-25 | Intervet International B.V. | Transdermale pharmazeutische zusammensetzung und verfahren zur behandlung von entzündungen bei rindern |
AU2009264334A1 (en) | 2008-06-27 | 2009-12-30 | Neurosearch A/S | Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
ES2461841T3 (es) | 2008-08-07 | 2014-05-21 | F. Hoffmann-La Roche Ag | Proceso para la preparación de un macrociclo |
GB0814991D0 (en) | 2008-08-15 | 2008-09-24 | Glaxo Group Ltd | Compounds |
AU2009293164B2 (en) | 2008-09-18 | 2015-07-09 | Northwestern University | NMDA receptor modulators and uses thereof |
WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
DE102009001460B4 (de) | 2009-03-11 | 2010-12-02 | Zf Friedrichshafen Ag | Ölbehälter |
WO2011003064A2 (en) | 2009-07-02 | 2011-01-06 | Naurex, Inc. | Methods of treating neuropathic pain |
US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
HUE043807T2 (hu) | 2009-10-05 | 2019-09-30 | Univ Northwestern | GLYX Alzheimer-kór, Parkinson-kór vagy Huntington-kór kezelésében történõ alkalmazásra |
AU2011215704B2 (en) | 2010-02-11 | 2015-07-23 | Northwestern University | Secondary structure stabilized NMDA receptor modulators and uses thereof |
KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도 |
US8097634B2 (en) | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
WO2012021712A1 (en) | 2010-08-12 | 2012-02-16 | Tetraphase Pharmaceuticals, Inc. | Tetracycline analogs |
US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
JP6035326B2 (ja) | 2011-04-27 | 2016-11-30 | ノースウェスタン ユニバーシティ | アルツハイマー病、ハンチントン病、自閉症及びその他の疾患を治療する方法 |
EP2723506B1 (de) | 2011-06-27 | 2017-02-15 | Koninklijke Philips N.V. | Ultraschall wandleranordnung und verfahren zu deren herstellung |
JP5427321B2 (ja) | 2011-07-27 | 2014-02-26 | アストラゼネカ アクチボラグ | 2−(2,4,5−置換−アニリノ)ピリミジン化合物 |
CA2898863A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
BR112015018087B1 (pt) | 2013-01-29 | 2022-09-20 | Aptinyx Inc | Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos |
PE20151438A1 (es) | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
US9708335B2 (en) * | 2013-01-29 | 2017-07-18 | Apytinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
WO2014120784A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
WO2017201283A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
PE20190503A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos |
PE20190502A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos |
PE20190501A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores nmda espiro-lactam y metodos de uso de los mismos |
PE20190500A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores del receptor nmda spiro-lactam y uso de los mismos |
SG11201900551WA (en) | 2016-08-01 | 2019-02-27 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
EP3746442A1 (de) | 2018-01-31 | 2020-12-09 | Aptinyx Inc. | Spiro-lactam-nmda-rezeptor-modulatoren und verwendungen davon |
US11578072B2 (en) | 2018-01-31 | 2023-02-14 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
US20210139489A1 (en) | 2019-11-11 | 2021-05-13 | Aptinyx Inc. | Methods of treating painful diabetic peripheral neuropathy |
-
2017
- 2017-08-01 SG SG11201900551WA patent/SG11201900551WA/en unknown
- 2017-08-01 KR KR1020197005662A patent/KR102465757B1/ko active IP Right Grant
- 2017-08-01 PE PE2019000297A patent/PE20190504A1/es unknown
- 2017-08-01 WO PCT/US2017/044841 patent/WO2018026782A1/en unknown
- 2017-08-01 IL IL286107A patent/IL286107B1/en unknown
- 2017-08-01 EA EA201990428A patent/EA201990428A1/ru unknown
- 2017-08-01 CN CN201780048070.6A patent/CN109890825B/zh active Active
- 2017-08-01 US US16/321,903 patent/US10918637B2/en active Active
- 2017-08-01 AU AU2017305240A patent/AU2017305240B2/en not_active Ceased
- 2017-08-01 EP EP17751913.9A patent/EP3490993B1/de active Active
- 2017-08-01 CA CA3031539A patent/CA3031539C/en active Active
- 2017-08-01 JP JP2019505249A patent/JP7032378B2/ja active Active
- 2017-08-01 MX MX2019001321A patent/MX2019001321A/es unknown
-
2019
- 2019-01-27 IL IL264495A patent/IL264495B/en unknown
- 2019-01-28 PH PH12019500206A patent/PH12019500206A1/en unknown
- 2019-01-30 CO CONC2019/0000943A patent/CO2019000943A2/es unknown
- 2019-01-30 CL CL2019000247A patent/CL2019000247A1/es unknown
-
2020
- 2020-12-01 US US17/108,199 patent/US11376250B2/en active Active
-
2022
- 2022-06-03 US US17/831,544 patent/US20230131402A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA3031539C (en) | 2023-11-28 |
JP2019527234A (ja) | 2019-09-26 |
IL286107B1 (en) | 2024-05-01 |
PE20190504A1 (es) | 2019-04-10 |
AU2017305240B2 (en) | 2021-12-09 |
EP3490993B1 (de) | 2023-12-06 |
IL264495B (en) | 2021-09-30 |
PH12019500206A1 (en) | 2019-06-17 |
US20190175588A1 (en) | 2019-06-13 |
AU2017305240A1 (en) | 2019-02-28 |
CN109890825B (zh) | 2022-03-11 |
US10918637B2 (en) | 2021-02-16 |
EP3490993C0 (de) | 2023-12-06 |
WO2018026782A1 (en) | 2018-02-08 |
KR102465757B1 (ko) | 2022-11-09 |
EP3490993A1 (de) | 2019-06-05 |
US20230131402A1 (en) | 2023-04-27 |
KR20190033594A (ko) | 2019-03-29 |
MX2019001321A (es) | 2019-07-04 |
EA201990428A1 (ru) | 2019-08-30 |
US20210322406A1 (en) | 2021-10-21 |
JP7032378B2 (ja) | 2022-03-08 |
US11376250B2 (en) | 2022-07-05 |
IL286107A (en) | 2021-10-31 |
CN109890825A (zh) | 2019-06-14 |
CA3031539A1 (en) | 2018-02-08 |
CO2019000943A2 (es) | 2019-02-08 |
CL2019000247A1 (es) | 2019-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201811559WA (en) | Cancer treatment combinations | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201900238UA (en) | Compounds and methods for modulation of smn2 |